-Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients-

-Semma to be acquired for $950 million in cash-

CAMBRIDGE, Mass., September 3, 2019 – Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash. Semma has demonstrated a differentiated approach to treat type 1 diabetes, a serious disease affecting over one million people in the United States alone. Semma has made two major scientific advances: the ability to produce large quantities of functional human pancreatic beta cells that restore insulin secretion and ameliorate hypoglycemia in animal models and a novel device that encapsulates and protects these cells from the immune system, enabling durable implantation without the need for ongoing immunosuppressive therapy.

Read more

– Stem cell-derived islets successfully reduce insulin requirements in diabetic non-human primates –

– Novel device successfully protects stem cell-derived islets in pigs without immunosuppression –

– Company plans to initiate two clinical trials in 2020 –

CAMBRIDGE, Mass., July 1, 2019 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the achievement of pre-clinical proof-of-concept based on data from its two lead programs for type 1 diabetes testing stem cell-derived islets (SC-islets) in both non-human primates and pigs.The data were presented by Felicia Pagliuca, Ph.D., Vice President of Cell Biology Research and Development, on Saturday, June 29th in a plenary oral presentation at the International Society for Stem Cell Research (ISSCR) Annual Meeting 2019 in Los Angeles.

Read more

CAMBRIDGE, Mass., May 29, 2019 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced that it has expanded its leadership team with the addition of Mary Kay Fenton as Chief Financial Officer.

Read more

CAMBRIDGE, Mass., May 8, 2019 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the journal Nature published data demonstrating improvements in the production of beta cells (cells that produce insulin) from stem cells. Led by Harvard University researchers in collaboration with scientists from Semma, the study characterized the types of cells produced by the applicable cell differentiation methods, and demonstrated biological and physical separation methods to increase the purity of beta cells in a sample of converted stem cells from 30 to 80 percent.

Read more

The 2018 Xconomy Awards Finalists Are…

Read more

VIDEO - JDRF Boston Gala: Nancy Jones Diabetes Champion Award Recipient, Semma Therapeutics

Read more

CAMBRIDGE, Mass., May 10, 2018 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano Sanna, Ph.D., as Chief Executive Officer and President. Dr. Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the Interim CEO and will remain as an advisor to the Company.

Read more

Semma Therapeutics Inc. has raised $114 million in a series B financing aimed at carrying its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes, through proof-of-concept studies. The company is preparing to file an investigational new drug (IND) application for the program while also exploring additional applications for its technologies.

Read more

Highly Oversubscribed Financing Brings Together Leading Syndicate of Investors to Advance Clinical Development of Novel Cell Therapy for Type 1 Diabetes

CAMBRIDGE, Mass., November 30, 2017 – Semma Therapeutics, a biotechnology company focused on the development of novel regenerative medicines, announced today the successful completion of a highly oversubscribed $114 million Series B financing. Proceeds will be used to bring Semma’s lead development program, encapsulated stem cell-derived islets, through clinical proof-of-concept in patients and to continue exploration of other regenerative medicine therapeutics. Semma’s proprietary technologies enable the generation of billions of functional, insulin-producing beta cells which have the potential to control blood sugar in people living with diabetes.

Read more

CAMBRIDGE, Mass., October 4, 2017 – Semma Therapeutics, a biopharmaceutical company developing stem cell-derived islet (SC-islet) technology for type 1 diabetes (T1D), today announced it will present on its encapsulated stem cell-derived human islets in a company overview at the Cell & Gene Meeting on the Mesa at 9:30 a.m. PDT on Thursday, Oct. 5 in La Jolla, California.

Read more

CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities. Financial terms of the investment were not disclosed.

Read more

CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.

Read more

CAMBRIDGE, Mass., September 12 th , 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapy for diabetes, announced today that it has accepted a $5 million grant from the California Institute of Regenerative Medicine (CIRM). The award provides funding to develop personalized cell therapy for the treatment of diabetes. Diabetic patients’ own cells will be collected, transformed first into stem cells and then differentiated into stem-cell derived pancreatic islets (SC-islets) to use as an investigational cell therapy for diabetes.

Read more

When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. “I remember at night, my wife and I pricking his heel, and saying ‘No, this can’t be, this can’t be,’” he says. “It felt like we had lost the lottery.”

Read more